

ASX Announcement
15 Mar 2023

emyria

A clinical stage biotech informed by patient experience.
Tackling unmet needs in neuroscience and mental health.

Broker Briefing Biotech & Nutrition Investor Webinar

Emyria Limited (ASX: EMD) (Emyria or the Company), a clinical stage biotech that operates clinical services, is pleased to advise shareholders and investors that the Company will be presenting as part of the ***free*** Broker Briefing Biotech & Nutrition Investor Webinar on Thursday 16 March 2023.

A presentation will be posted to the ASX platform on the morning of the presentation.

Date: 16 March 2023

Time: 11:30am AEDT / 8:30am AWST

Presenter: Managing Director, Dr Michael Winlo, presenting at 11:50am AEDT / 8:50am AWST

The Company invites shareholders, investors, and media to participate in this digital event by **registering online** via the link below:

https://us06web.zoom.us/webinar/register/6416518025748/WN_Hwj9PbRTRE2qtdPZ0rtPSA

Participants will be able to submit questions via the panel throughout the presentation, however, we encourage shareholders and investors to send through questions via email beforehand info@brokerbriefing.com

This announcement has been approved for release to ASX by the Managing Director of the Company.

emyria

UPCOMING MILESTONES

CLINICAL PROGRAMS

"direct-to-consumer"
Formulation optimisation (RX5) ✓
Phase 1 study done ✓
Phase 3 commencement ✓
Regulatory submission
Commercial strategy **Australia**
Commercial strategy **Europe**
Commercial strategy **USA**

"prescription medicine"
Formulation optimisation (RX7) ✓
Phase 1
Pre-IND **(FDA)**
Pivotal trials

PRE-CLINICAL + THERAPY PROGRAMS

New Drug Discovery
Continuous creation & screening ✓
First patent family filed ✓
US-focused preclinical program ✓
Metabolic studies ✓
Lead selection
Phase 1 trials
Global commercial strategy

MDMA-assisted therapy
Protocol developed ✓
Clinical partnerships ✓
Real-World Data system ✓
MDMA supply secured ✓
Therapist training
First patient
Global commercial strategy

ABOUT EMYRIA | emyria.com

Emyria Limited is a clinical drug development and care delivery company focused on accelerating drug development and improving patient outcomes in neuroscience and mental health via:

- **Drug Development:** Multiple, proprietary, Ultra-Pure cannabinoid dose forms suitable for registration against multiple indications. Emyria's first dose form, EMD-RX5, is in Phase 3 trials.
- **New Drug Discovery:** Inspired by MDMA, Emyria is developing one of the world's largest libraries of MDMA-like compounds with partner, the University of Western Australia.
- **Proprietary Real-World Data (RWD):** Emyria gathers robust and ethically-sourced data with patients cared for at Emyria's own specialist clinical service (Emerald Clinics). Emyria RWD can help support drug development and care model improvement.

EMYRIA'S INTERACTIVE INVESTOR HUB

Investorhub.emyria.com Interact with Emyria's announcements and updates by asking questions and comments, which our team can respond to where possible.

CAUTIONARY NOTE ON FORWARD-LOOKING STATEMENTS Any statements in this press release about future expectations, plans and prospects for the Company, the Company's strategy, future operations, and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the Company's ability to successfully develop its product candidates and timely complete its planned clinical programs and the Company's ability to obtain marketing approvals for its product candidates. In addition, the forward-looking statements included in this press release represents the Company's views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.

FOR FURTHER INFORMATION

Dr. Michael Winlo
Managing Director
+61 (0) 8 6559 2800
mwinlo@emyria.com

Lexi O'Halloran
Investor Relations
+61 (0) 404 577 076
investors@emyria.com

Andrew Williams
Media Relations
+61 (0) 412 614 125
awilliams@emyria.com

Sufian Ahmad
Corporate Advisor
+61 (0) 412 316 162
info@62capital.com.au